MRD-Guided Surveillance in Operable Colon Adenocarcinoma (I-III)(SURVEILLANCE-I)

This is a multicenter, prospective, observational study designed to evaluate the effectiveness of ctDNA-based MRD monitoring in predicting disease recurrence and survival outcomes in patients with stage I-III operable colon adenocarcinoma. The study will enroll 390 patients who have not previously received chemotherapy, radiotherapy, or targeted therapy. Key Objectives: Primary Objective: To explore the correlation between MRD status and recurrence-free survival (RFS) in stage I-III colon adenocarcinoma patients. Secondary Objectives: To assess the relationship between MRD status and 1-year/2-year recurrence-free survival (1yRFS, 2yRFS). To evaluate the association between MRD status and overall survival (OS). Exploratory Objective: To determine the average time by which MRD detection precedes imaging-based detection of disease recurrence. Study Design: Patients will undergo blood sampling at baseline (pre-surgery), post-surgery (7±2 days), and during follow-up visits at 1, 3, 6, 9, 12, 18, 24, and 36 months. MRD status will be assessed using ctDNA methylation-based PCR technology, which offers a rapid and cost-effective alternative to traditional NGS-based methods. Statistical Analysis: The study will use Kaplan-Meier survival analysis to estimate RFS and OS. Cox regression models will be employed to determine whether MRD status can serve as a prognostic factor for disease recurrence. Ethical Considerations: The study adheres to the principles of the Declaration of Helsinki and Chinese Good Clinical Practice (GCP) guidelines. Informed consent will be obtained from all participants, and their privacy and confidentiality will be strictly maintained. Expected Outcomes: The study aims to validate the clinical utility of ctDNA-based MRD monitoring in predicting recurrence and survival outcomes, potentially offering a more effective tool for postoperative surveillance and treatment planning in colon cancer patients.